Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Misonix Inc. (MSON) -- Ignore unavailable to you. Want to Upgrade?

To: cape radical who wrote (600)	1/7/1998 4:10:00 PM
From: Candle stick	Respond to of 947

Hi cape, still here.....I bought some more MSON at low 7's during yearend....holding tight here...what a disappointment to see it so low. On the other hand, what an opportunity to load up on stock. I expect that we wont see much upside until earnings are released. As far as I know the company is solid with new products and a large recent order from US Surgical for 3.8 million dollars......I think patience is in order....if I hear anything to change my mind I will certainly let you know....best of luck this year......I am looking to short AMZN bigtime before earnings release (or rather lack of earnings release) around end of January........;^)

To: cape radical who wrote (600)	1/7/1998 9:48:00 PM
From: Candle stick	Respond to of 947

Cape, I am going to copy a post I found on AOL to update you whats up at MSON.....the poster, Wesley, always seems to be very well informed on this company......... "Subject: MSON Update Date: Wed, Jan 7, 1998 16:49 EST From: Wesley0428 Message-id: <19980107214900.QAA23746@ladder01.news.aol.com> The stock price seems to expect a lousy Q2 and the loss of the USS manufacturing contract for cannulas. Q2 won't be so bad and, so far, the contract with USS for cannula manufacturing is still in place and Misonix is shipping aggressively against that contract. Despite the announced drop off in Lysonix demand, I expect Q2 revenues to match or exceed Q1. Q3 revenues should resume excellent growth rates. I'm looking fo $.12 for Q2, obviously a lower number than before we learned of the Lysonix inventory problems, but less of a disaster than I think the current stock price reflects. The only analyst following MSON is looking for $.10. I've also heard rumors that MDA is interested in acquiring Misonix. I have multiple sources who have heard this rumor. Most of those sources don't believe it and Misonix says no discussions have taken place. For what it's worth, I think it true, but that doesn't mean it'll necessarily occur. Remember MDA is in the process of going public via a reverse merger with Direct Connect (KIDZ). I would assume they would wait until that merger is complete (I'm hearing March), before talking to Misonix. Bottom line is I'm very comfortable holding MSON at this price, much more upside than downside. Expect earnings by Jan. 23 at latest. "